Full-Time
Medical Science Liaison
Confirmed live in the last 24 hours
ArteraAI
11-50 employees
Personalizes prostate cancer therapy using deep learning
Compensation Overview
$160k - $180kAnnually
Junior, Mid
Remote in USA
- Advanced degree (MD, PhD, or PharmD) in a relevant scientific or clinical field preferred
- 2+ years of experience in biotechnology/pharma, clinical, or research fields preferred
- Prior MSL experience is strongly preferred
- Experience in oncology or diagnostics/biomarkers is strongly preferred
- Excellent verbal and written communication skills with external stakeholders
- Strong attention to detail and organizational skills
- Analytical thinker with problem-solving skills and the ability to adapt to changing priorities and deadlines
- Ability to travel up to 60% of the time to meet with clinicians at their institutions, offices, and/or oncology conferences
- Identify and engage with key clinicians to share scientific expertise and develop peer-level relationships
- Interpret and effectively communicate relevant medical and scientific information
- Attend conferences and symposia for the purpose of providing medical and scientific support to internal and external customers
- Obtain and provide actionable insights that enhances the value and appropriate use of Artera’s products to internal stakeholders
- Respond to medical inquiries with clinical and scientific information supporting the appropriate use of Artera’s products
- Support development of clinical evidence studies by evaluating and managing investigator-initiated research proposals
- Maintain expertise in disease state management, emerging biomarkers,and the competitive landscape
- Work cross-functionally and compliantly with internal partners to provide medical and scientific expertise
- Adhere to internal processes as well as regulatory and compliance requirements
- Develop understanding of oncology customer segments and market dynamics
ArteraAI focuses on personalizing therapy for prostate cancer through its main product, the ArteraAI Prostate Test, which is a clinical laboratory test developed in-house. This test utilizes advanced multi-modal deep learning techniques to analyze patient data and provide tailored treatment options. Unlike many competitors, ArteraAI's test is not experimental; it is used in actual clinical settings, ensuring reliability and effectiveness. The company serves healthcare providers, hospitals, and individual patients, generating revenue through the sale of their prostate test. ArteraAI stands out in the healthcare technology market due to its commitment to scientific rigor, as demonstrated by its reliance on randomized phase III clinical trials, and its CLIA certification, which enhances its credibility. The goal of ArteraAI is to improve prostate cancer treatment outcomes by offering personalized therapy options and continuously advancing their technology through research and development.
Company Stage
Series C
Total Funding
$110M
Headquarters
Menlo Park, California
Founded
2021
6 month growth
↑ 8%1 year growth
↑ 30%2 year growth
↑ 74%
Simplify's Take
What believers are saying
- ArteraAI's recent $20 million funding round from prominent investors supports its mission to advance personalized cancer therapy and expand internationally.
- Partnerships with organizations like Movember and GenesisCare enhance ArteraAI's credibility and broaden its impact in the global healthcare community.
- Inclusion in the NCCN Guidelines and Medicare approval for the ArteraAI Prostate Test ensures broader accessibility and recognition in the medical community.
What critics are saying
- The highly specialized focus on prostate cancer may limit market size and growth potential compared to companies with a broader oncology focus.
- Reliance on continuous validation and clinical trials could delay product updates and market expansion.
What makes ArteraAI unique
- ArteraAI leverages advanced multi-modal deep learning techniques to personalize prostate cancer therapy, setting it apart from traditional treatment methods.
- The ArteraAI Prostate Test is the first AI-enabled predictive and prognostic test included in the NCCN Guidelines for localized prostate cancer, highlighting its clinical validation and reliability.
- Their focus on high complexity clinical laboratory tests, backed by randomized phase III clinical trials, ensures a high level of scientific rigor and reliability.